Drug Discovery World

DECEMBER 11, 2023

The active component of MC2-25 CKD is a di-peptide, which is formulated in cream based on MC2 Therapeutics’ formulation and drug delivery system PAD Technology. This new understanding of the role played by carbamylation in CKD-aP is very exciting and offers hope to millions of patients.”

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Protein Trials 52

Roots Analysis

MARCH 3, 2022

Majority of these are biologics and are being developed for the treatment of different disease conditions, including dermatological, genetic, hematological and vascular, immunological and inflammatory, infectious, neurological, ophthalmic, renal disorders. Next Generation Complement Therapeutics. Broad Clinical Trial Landscape. Web: [link].

Drug Delivery Systems 52

Drug Delivery Systems Marketing Immune Response Dermatology 52

The Pharma Data

NOVEMBER 4, 2020

TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co.

Licensing 40

Licensing Licensing Dermatology Production 40

The Pharma Data

MARCH 3, 2021

Mylan) and Kindeva Drug Delivery L.P. The Company’s growing presence in immunology is focused on five mid- to late-stage franchises with multi-disease potential, in areas including rheumatology (including systemic lupus erythematosus), dermatology, gastroenterology, and systemic eosinophilic-driven diseases.

Dermatology 52

Dermatology Drug Delivery Medicine Containment 52